“…It is the only HATi in clinical trials (Table 8) and exhibits great promise as a therapeutic agent. Its applications include atopic asthma (Kobayashi et al., 1997), chronic obstructive pulmonary disease (Rennolds et al., 2012), multiple myeloma (Ghoneum and Gollapudi, 2011), irritable bowel syndrome (Binion et al., 2008; Rapin and Wiernsperger, 2010), ulcerative colitis (Baliga et al., 2012), Crohn's disease (Mouzaoui et al., 2012), breast cancer (Nagaraju et al., 2012), Alzheimer's disease (Darvesh et al., 2012; Huang et al., 2012), pancreatic cancer (Dandawate et al., 2012; Veeraraghavan et al., 2011), colorectal cancer (Guo et al., 2012; Lin et al., 2011), diabetes (Abdel Aziz et al., 2012), and psoriasis (Kurd et al., 2008).…”